Revenue Performance - Revenue for the first quarter of fiscal 2025 was 81.5billion,representinga12.8percentincreaseyear−over−year,drivenbya13.6percentincreaseintheU.S.HealthcareSolutionssegment[1][5]−U.S.HealthcareSolutionsrevenuewas74.0 billion, an increase of 13.6 percent year-over-year, with segment operating income rising 9.9 percent to 767.3million[8][10]−InternationalHealthcareSolutionsrevenuewas7.5 billion, a 5.5 percent increase year-over-year, with operating income decreasing by 2.9 percent[10] - Total revenue for the same period increased by 12.8% year-over-year, reaching 81.49billion,drivenbya13.681.5 billion, negatively impacted by foreign currency translation of 216.8million,resultinginconstantcurrencyrevenueof81.7 billion[42] - The International Healthcare Solutions segment reported revenue of 7.5billion,withaconstantcurrencyrevenueof7.7 billion after accounting for foreign currency translation[42] Earnings and Income - Adjusted diluted EPS guidance for fiscal 2025 has been raised to a range of 15.25to15.55, up from the previous range of 15.15to15.45[2][16] - Operating income for the first quarter was 706million,a14.2percentdecreasecomparedtothesameperiodlastyear,primarilyduetoincreasedoperatingexpenses[4][5]−Adjustedoperatingincomeforthefirstquarterwas949 million, a 7.2 percent increase compared to the prior year[9] - Net income attributable to Cencora, Inc. was 488,600,adecreaseof18.8601,500 in the prior year, resulting in diluted earnings per share of 2.50,down16.1727,796, reflecting a 13.7% increase compared to the prior year, with adjusted diluted earnings per share of 3.73[27]−GAAPnetincomeforthethreemonthsendedDecember31,2023,was601.5 million, with diluted earnings per share of 2.98[30]ExpensesandCosts−Totaloperatingexpensesincreasedby12.51,851,784, with distribution, selling, and administrative expenses rising by 5.2% to 1,472,055[25]−Thecompanyincurreda35.5 million loss on the divestiture of non-core businesses during the quarter[27] - Interest expense decreased by 31.1% to 27,933,downfrom40,564 in the previous year[25] - Net interest expense decreased by 31.1 percent to 27.9million,attributedtohigherinterestincomefromincreasedcashbalances[5][9]DividendsandShareholderReturns−Thecompanydeclaredaquarterlycashdividendof0.55 per common share, payable on March 3, 2025[17] Acquisitions and Strategic Moves - The acquisition of Retina Consultants of America was completed on January 2, 2025, enhancing the company's leadership in Specialty healthcare services[3][11] - The company plans to finance a portion of the upcoming acquisition of Retina Consultants of America with 1.8billioninseniornotes[37]TaxandFinancialMetrics−Theeffectivetaxrateforthefirstquarterwas20.4percent,downfrom23.0percentintheprioryear[5]−Theadjustedeffectivetaxrateiscalculatedbydividingadjustedincometaxexpensebyadjustedincomebeforeincometaxes,providingaclearerviewofthecompany′staxperformanceexcludingunusualitems[44]CashFlowandLiquidity−Cashandcashequivalentsattheendoftheperiodtotaled3.22 billion, an increase from 3.13billionattheendofthepreviousquarter[35]−Thecompanyexperiencedanetcashusedinoperatingactivitiesof2.72 billion, compared to 885.16millionprovidedinthesameperiodlastyear[37]−Long−termdebtincreasedto5.94 billion, up from $3.81 billion in the previous quarter[35] Non-GAAP Measures and Adjustments - Adjusted diluted earnings per share excludes impacts from antitrust litigation settlements, LIFO expense, and other non-recurring items, reflecting ongoing operational performance[44] - Adjusted net income attributable to the company excludes unusual, non-operating, unpredictable, non-recurring, or non-cash items, providing a clearer picture of ongoing performance[44] - Adjusted gross profit margin is calculated as adjusted gross profit divided by total revenue, providing insight into the company's core operating performance[41] - The company emphasizes the importance of non-GAAP financial measures to evaluate operating performance and financial planning[41]